Buruli ulcer

Dr Mark Wansbrough-Jones

Nationality: British

E-mail: wansbrou@sghms.ac.uk

Present positions

  • Senior Lecturer, Department of Cellular & Molecular Medicine, Infectious Diseases, St George’s, University of London (appointed teacher & examiner)
  • Consultant Physician and Head of Clinical Infection Unit, St George’s Hospital, London
  • Programme Director for South Thames Infectious Disease Specialist Training Programme

Areas of expertise/interest

  • Experimental chemiotherapy
  • Clinical trials
  • Immunology

Recent publications

  • Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis. 2009 Dec 1;200(11):1675-84. [Abstract/Free full text]
  • Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, Lartey A, Adentwe E, Opare W, Asiedu KB, Wansbrough-Jones M. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol. 2009 Apr;47(4):924-6. Epub 2009 Feb 9. [Abstract/Free full text]
  • Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, Johnson RC, Pedrosa J, Phanzu DM, Phillips RO, Pluschke G, Siegmund V, Singh M, van der Werf TS, Wansbrough-Jones M, Portaels F. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol. 2009 May;198(2):69-77. Epub 2009 Feb 7. [Abstract/Free full text]
  • Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol. 2009 Jan;16(1):61-5. Epub 2008 Nov 12. [Abstract/Free full text]
  • Asiedu K, Wansbrough-Jones M. Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies. Med J Aust. 2007 Jan 15;186(2):55-6. [Abstract/Free full text]
  • Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet. 2006 Jun 3;367(9525):1849-58. Review. [Abstract]
  • Phillips R, Horsfield C, Mangan J, Laing K, Etuaful S, Awuah P, Nyarko K, Osei-Sarpong F, Butcher P, Lucas S, Wansbrough-Jones M. Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun. 2006 May;74(5):2917-24. [Abstract/Free full text]
  • Phillips R, Horsfield C, Kuijper S, Sarfo SF, Obeng-Baah J, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol. 2006 Feb;13(2):253-7. [Abstract]
  • van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, Wansbrough-Jones MH, Johnson PD, Portaels F, van der Graaf WT, Asiedu K. Mycobacterium ulcerans disease. Bull World Health Organ. 2005 Oct;83(10):785-791. Epub 2005 Nov 10. [Abstract]
  • Phillips R, Horsfield C, Kuijper S, Lartey A, Tetteh I, Etuaful S, Nyamekye B , Awuah P, Nyarko K.M, Osei-Sarpong F, Lucas S, Kolk A.H.J, Wansbrough-Jones M. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol. 2005 Aug;43(8):3650-6. [Abstract]
  • Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu G, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005 Aug;49(8):3182-6. [Abstract]
  • Wansbrough-Jones MH, Phillips R. Buruli ulcer: A neglected but treatable disease that unnecessarily scars African children for life. BMJ. 2005 Jun 18;330(7505):1402-3.
Share